Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclosporine A as treatment of esophageal involvement in dermatomyositis.

Literature DB >> 16900376

Cyclosporine A as treatment of esophageal involvement in dermatomyositis.

Sumiyuki Mii¹, Shiro Niiyama, Mai Kusunoki, Satoru Arai, Kensei Katsuoka.

Abstract

We report a case of a 70-year-old man with dermatomyositis complicated by esophageal involvement resistant to corticosteroid therapy. It had serious and potentially life-threatening implications, resulting in impossible oral feeding. This condition was successfully resolved by administration of cyclosporine A.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16900376 DOI： 10.1007/s00296-006-0168-6

Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631

14 in total

1. The association of plasma exchange synchronized with intravenous gamma globulin therapy in severe intractable polymyositis.

Authors: S Herson; P Cherin; A Coutellier
Journal: J Rheumatol Date: 1992-05 Impact factor: 4.666

Review 2. Update on therapy for refractory dermatomyositis and polymyositis.

Authors: L Villalba; E M Adams
Journal: Curr Opin Rheumatol Date: 1996-11 Impact factor: 5.006

3. Survival in polymyositis: corticosteroids and risk factors.

Authors: J R Carpenter; T W Bunch; A G Engel; P C O'Brien
Journal: J Rheumatol Date: 1977 Impact factor: 4.666

4. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle.

Authors: S Matsubara; S Hirai; Y Sawa
Journal: J Neuroimmunol Date: 1997-06 Impact factor: 3.478

Review 5. Evaluation and treatment of speech and swallowing disorders associated with myopathies.

Authors: B C Sonies
Journal: Curr Opin Rheumatol Date: 1997-11 Impact factor: 5.006

6. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice.

Authors: O C Meijer; E C de Lange; D D Breimer; A G de Boer; J O Workel; E R de Kloet
Journal: Endocrinology Date: 1998-04 Impact factor: 4.736

Review 7. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.

Authors: S B Kaye
Journal: Curr Opin Oncol Date: 1998-08 Impact factor: 3.645

8. Pulmonary involvement in polymyositis and in dermatomyositis.

Authors: I Marie; P Y Hatron; E Hachulla; B Wallaert; U Michon-Pasturel; B Devulder
Journal: J Rheumatol Date: 1998-07 Impact factor: 4.666

9. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease.

Authors: M C Dalakas
Journal: J Clin Immunol Date: 1995-11 Impact factor: 8.317

Review 10. Current treatment of the inflammatory myopathies.

Authors: M C Dalakas
Journal: Curr Opin Rheumatol Date: 1994-11 Impact factor: 5.006

4 in total

Review 1. Therapeutic approaches in myositis.

Authors: Rohit Aggarwal; Chester V Oddis
Journal: Curr Rheumatol Rep Date: 2011-06 Impact factor: 4.686